Judith Klimovsky
Corporate Officer/Principal chez GENMAB A/S
Fortune : 2 M $ au 29/02/2024
Profil
Judith Klimovsky is Chief Development Officer & Executive VP at Genmab A.
In her past career Dr. Klimovsky occupied the position of Senior Vice President & Head-Clinical Development at Novartis AG and Senior Vice President & Head-Clinical Development at Novartis Pharma AG (a subsidiary of Novartis AG).
She received a doctorate from the University of Buenos Aires School of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
GENMAB A/S
0,01% | 14/02/2024 | 8 740 ( 0,01% ) | 2 M $ | 29/02/2024 |
28/04/2023 | 14 602 ( 0,12% ) | 1 168 $ | 29/02/2024 |
Postes actifs de Judith Klimovsky
Sociétés | Poste | Début |
---|---|---|
GENMAB A/S | Corporate Officer/Principal | 09/02/2017 |
Anciens postes connus de Judith Klimovsky
Sociétés | Poste | Fin |
---|---|---|
BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | 23/02/2024 |
NOVARTIS AG | Corporate Officer/Principal | 01/02/2017 |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/01/2017 |
Formation de Judith Klimovsky
University of Buenos Aires School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
NOVARTIS AG | Health Technology |
GENMAB A/S | Health Technology |
Entreprise privées | 2 |
---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |